How we treat patients with metastatic HER2-positive breast cancer

HER2-positive breast cancer represents 15%-20% of breast malignancies and is characterized by an aggressive behavior and high recurrence rates. Anti-HER2-directed agents represent the mainstay of treatment of patients with HER2-positive metastatic breast cancer (MBC). In this review we propose a tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Nader-Marta, G., Martins-Branco, D., de Azambuja, E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8741455/
https://www.ncbi.nlm.nih.gov/pubmed/34995893
http://dx.doi.org/10.1016/j.esmoop.2021.100343

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8741455/
https://www.ncbi.nlm.nih.gov/pubmed/34995893
http://dx.doi.org/10.1016/j.esmoop.2021.100343

Ejemplares similares